GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cresco Labs CL.CN · CAD

Health Care · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.75

-5.06%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$655.8m

FY2014FY2025

Net income

−$135.4m

FY2014FY2025

Free cash flow

$34.7m

FY2014FY2025

Shareholders' equity

$340.4m

FY2014FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2014
Revenue$655.8m$724.3m$770.9m$842.7m$821.7m$476.3m$128.5m$43.3m——
Research and development—————————$9,800
Operating income$76.9m$109.3m$62.9m$56.9m$87.8m$46.7m−$43.0m$6.6m−$44,417−$46,400
Net income−$135.4m−$74.4m−$175.5m−$212.0m−$319.6m−$81.9m−$43.2m−$1.9m−$85,354−$74,300
Diluted earnings per share-0.38-0.21-0.52-0.70-1.17-0.37-0.33-0.02-2.45-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2014
Total assets$1.20bn$1.36bn$1.36bn$1.58bn$1.78bn$1.33bn$616.6m$318.1m$1,838$113,200
Total liabilities$944.8m$967.2m$930.4m$996.0m$982.7m$608.4m$293.9m$35.1m$1.1m$912,100
Debt$417.1m$460.8m$497.7m$469.1m$465.1m$169.5m———$100
Shareholders' equity$340.4m$474.9m$505.7m$627.0m$755.6m$574.4m$187.1m$121.0m−$1.1m−$798,900
Shares outstanding360m348m340m301m274m223m132m110m0m—

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2014
Cash from operations$72.9m$132.5m$58.6m$18.7m$14.5m−$7.8m−$25.2m−$9.9m−$4.9m−$38,100
Capital spending−$38.2m−$23.5m−$57.9m−$86.1m−$93.9m−$87.2m−$91.7m−$29.2m−$4.1m—
Free cash flow$34.7m$109.0m$681,000−$67.4m−$79.4m−$95.0m−$116.9m−$39.1m−$9.0m−$38,100
Dividends paid—————−$162,000−$2.9m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$173.3m$151.3m$161.6m$164.9m$163.6m$165.8m$175.9m$179.8m
Operating income$13.4m$11.2m$17.8m$20.2m$15.8m$13.6m$16.1m$28.7m
Net income$16.8m−$13.1m−$87.6m−$17.1m−$16.3m−$14.4m−$4.4m−$10.5m
Diluted earnings per share0.05-0.04-0.24-0.05-0.05-0.04-0.01-0.03
Cash from operations$15.0m−$5.0m$27.0m$6.0m$8.0m$30.0m$29.0m$49.0m
Capital spending−$10.0m−$9.0m−$10.0m−$7.0m−$13.0m−$7.0m−$3.0m−$6.0m
Free cash flow$5.0m−$14.0m$17.0m−$1.0m−$5.0m$23.0m$26.0m$43.0m
Total assets$1.26bn$1.20bn$1.20bn$1.28bn$1.35bn$1.36bn$1.36bn$1.38bn
Debt$419.6m$418.2m$417.1m$326.7m$371.7m$370.6m$460.8m$499.3m
Shareholders' equity$358.7m$336.0m$340.4m$428.3m$444.5m$461.9m$474.9m$456.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-8.0%6.6%—
Operating income10.6%10.5%—
Net income-13.9%10.6%111.9%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin13.5%10.2%10.3%—
Net margin-15.2%-20.0%-23.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-3.2-2.7-1.5-1.5-3.1-14.7
Price to sales0.70.30.30.41.22.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.